With an annual R & D investment of EUR 1bn , we are committed to growing our business in specialist-focused therapeutic areas such as Neurodegenerative Diseases and Oncology , as well as new therapeutic areas potentially arising out of our research and development in Autoimmune and Inflammatory Diseases .